Safety and efficacy of intralesional steroid injection for aggressive fibromatosis

Table 1 Demographic data and initial evaluation

Case no.	Age	Gender	Dose (mg)‡	BMI (kg/m²)	Site of tumor	Treatment history
01†	44	Male	80	30.04	Lower back	Post-3rd surgery with S and SD
02	51	Female	47	18.83	Lower back	Post-1st surgery with S and PD
03	30	Female	52	21.64	Shoulder	Post-3rd surgery with S and PD
04	23	Male	68	23.53	Lower neck	Post-2nd surgery with S and PD
05	55	Female	58	25.78	Shoulder	Post-2nd surgery with S and PD
06	45	Female	53	20.70	Thigh	Post-3rd surgery with S and SD
07	18	Male	60	20.05	Shoulder	Post-1st surgery with S and PD
08	56	Female	65	24.77	Shoulder	Post-5th surgery with S and SD
09	40	Female	58	22.65	Forearm	Post-3rd surgery with S and PD
10†	20	Male	65	21.22	Thigh	Post-3rd surgery with AS and PD

S symptomatic disease including pain and/or discomfort, AS asymptomatic disease, SD stable disease, PD progressive disease
†Dropped out of study,
‡mg/episode

ISSN: 1477-7819